To Assess the Efficacy and Safety of Vildagliptin in Patients with Type 2 Diabetes
Phase 1
- Conditions
- Type 2 Diabetes
- Registration Number
- JPRN-jRCT2080220150
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 264
Inclusion Criteria
Inclusion criteria
- Male or female aged 20 to 75 years old
- Diagnosis as Type 2 Diabetes
- Patients who have been placed on dietary therapy / exercise therapy, without achievement of glycemic control
- Outpatients
Exclusion criteria
- - Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- Significant heart diseases
- Significant diabetic complications
Other protocol-defined exclusion criteria may apply.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change from baseline in HbA1c at 12 weeks
- Secondary Outcome Measures
Name Time Method